EUR USD GBP
+353-1-416-8900REST OF WORLD
1-800-526-8630U.S. (TOLL FREE)

Acinetobacter Infections - Pipeline Review, H1 2015

  • ID: 3293065
  • Report
  • May 2015
  • 114 pages
  • Global Markets Direct
1 of 4

FEATURED COMPANIES

  • Achaogen Inc.
  • AvidBiotics Corp.
  • LegoChem Biosciences, Inc
  • Northern Antibiotics Oy
  • Omnia Molecular Ltd.
  • Sealife PHARMA GMBH
  • MORE
Acinetobacter Infections - Pipeline Review, H1 2015

Summary

This, ‘Acinetobacter Infections - Pipeline Review, H1 2015’, provides an overview of the Acinetobacter Infections’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Acinetobacter Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Acinetobacter Infections and special features on late-stage and discontinued projects.

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Acinetobacter Infections
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Acinetobacter Infections and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Acinetobacter Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Acinetobacter Infections pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Acinetobacter Infections
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Acinetobacter Infections pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Achaogen Inc.
  • AvidBiotics Corp.
  • LegoChem Biosciences, Inc
  • Northern Antibiotics Oy
  • Omnia Molecular Ltd.
  • Sealife PHARMA GMBH
  • MORE
List of Tables
List of Figures
Introduction
REPORT COVERAGE
Acinetobacter Infections Overview
Therapeutics Development
Pipeline Products for Acinetobacter Infections - Overview
Pipeline Products for Acinetobacter Infections - Comparative Analysis
Acinetobacter Infections - Therapeutics under Development by Companies
Acinetobacter Infections - Therapeutics under Investigation by Universities/Institutes
Acinetobacter Infections - Pipeline Products Glance
Clinical Stage Products
Early Stage Products
Acinetobacter Infections - Products under Development by Companies
Acinetobacter Infections - Products under Investigation by Universities/Institutes
Acinetobacter Infections - Companies Involved in Therapeutics Development
Achaogen Inc.
Adenium Biotech ApS
AmpliPhi Biosciences Corporation
Aridis Pharmaceuticals LLC
AstraZeneca PLC
AvidBiotics Corp.
ConjuGon, Inc.
Emergent BioSolutions Inc.
FAB Pharma
LegoChem Biosciences, Inc
Melinta Therapeutics, Inc
Microbiotix, Inc.
Northern Antibiotics Oy
Nosopharm SAS
Novan, Inc.
Omnia Molecular Ltd.
Pfizer Inc.
Phylogica Limited
Sarepta Therapeutics, Inc.
Sealife PHARMA GMBH
Shionogi & Co., Ltd.
Synthetic Biologics, Inc.
Techulon, Inc.
Trana Discovery, Inc.
Vaxdyn, S.L.
Acinetobacter Infections - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
A-3APO - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AA-139 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ACHN-975 Prodrug - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Antibiotics to Inhibit tRNA For Hospital-Acquired Gram-Negative Bacterial Infections - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Antisense Oligonucleotide for Acinetobacter baumannii Infections - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Antisense Oligonucleotide for Acinetobacter Baumannii Infections - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AR-401 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Biologics for Acinetobacter Baumanii - Drug Profile
Product Description
Mechanism of Action
R&D Progress
BXN-112 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cephalosporin + Beta-Lactamase Inhibitor - Drug Profile
Product Description
Mechanism of Action
R&D Progress
EV-035 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Fab-001 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
GN-4474 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
LCB-100200 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MBX-1162 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MDN-0057 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MDN-0058 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MDN-0059 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MDN-0060 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Monoclonal Antibodies for Gram-Negative Bacterial Infections - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NAB-7061 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NAB-739 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NAB-741 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NOSO-95300 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NVN-1000 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NVN-4428 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Recombinant Proteins to Disrupt Bacterial Cell Membrane for Bacterial Infections - Drug Profile
Product Description
Mechanism of Action
R&D Progress
RX-05 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
RXP-873 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
S-649266 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Second Generation Apidaecin Analogs for Gram-Negative Bacterial Infections - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SLP-0905 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecule for Acinetobacter baumannii Infections - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecule for Gram-Negative Nosocomial Infections - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecule to Inhibit Lipopolysaccharide for Nosocomial Infections - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecules for Gram-Negative Bacterial Infections - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecules for Multi-Drug Resistant Bacterial Infections - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecules to Inhibit LpxC for Gram-Negative Bacterial Infections - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecules to Inhibit NDH-1 for Acinetobacter baumannii Infections - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecules to Inhibit Tryptophanyl-tRNA synthetase for Bacterial Infections - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SYN-001 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
VXD-001 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
VXD-003 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Acinetobacter Infections - Recent Pipeline Updates
Acinetobacter Infections - Dormant Projects
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Acinetobacter Infections, H1 2015
Number of Products under Development for Acinetobacter Infections - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Number of Products under Development by Companies, H1 2015 (Contd..1)
Number of Products under Investigation by Universities/Institutes, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Development, H1 2015
Products under Development by Companies, H1 2015
Products under Development by Companies, H1 2015 (Contd..1)
Products under Development by Companies, H1 2015 (Contd..2)
Products under Investigation by Universities/Institutes, H1 2015
Acinetobacter Infections - Pipeline by Achaogen Inc., H1 2015
Acinetobacter Infections - Pipeline by Adenium Biotech ApS, H1 2015
Acinetobacter Infections - Pipeline by AmpliPhi Biosciences Corporation, H1 2015
Acinetobacter Infections - Pipeline by Aridis Pharmaceuticals LLC, H1 2015
Acinetobacter Infections - Pipeline by AstraZeneca PLC, H1 2015
Acinetobacter Infections - Pipeline by AvidBiotics Corp., H1 2015
Acinetobacter Infections - Pipeline by ConjuGon, Inc., H1 2015
Acinetobacter Infections - Pipeline by Emergent BioSolutions Inc., H1 2015
Acinetobacter Infections - Pipeline by FAB Pharma, H1 2015
Acinetobacter Infections - Pipeline by LegoChem Biosciences, Inc, H1 2015
Acinetobacter Infections - Pipeline by Melinta Therapeutics, Inc, H1 2015
Acinetobacter Infections - Pipeline by Microbiotix, Inc., H1 2015
Acinetobacter Infections - Pipeline by Northern Antibiotics Oy, H1 2015
Acinetobacter Infections - Pipeline by Nosopharm SAS, H1 2015
Acinetobacter Infections - Pipeline by Novan, Inc., H1 2015
Acinetobacter Infections - Pipeline by Omnia Molecular Ltd., H1 2015
Acinetobacter Infections - Pipeline by Pfizer Inc., H1 2015
Acinetobacter Infections - Pipeline by Phylogica Limited, H1 2015
Acinetobacter Infections - Pipeline by Sarepta Therapeutics, Inc., H1 2015
Acinetobacter Infections - Pipeline by Sealife PHARMA GMBH, H1 2015
Acinetobacter Infections - Pipeline by Shionogi & Co., Ltd., H1 2015
Acinetobacter Infections - Pipeline by Synthetic Biologics, Inc., H1 2015
Acinetobacter Infections - Pipeline by Techulon, Inc., H1 2015
Acinetobacter Infections - Pipeline by Trana Discovery, Inc., H1 2015
Acinetobacter Infections - Pipeline by Vaxdyn, S.L., H1 2015
Assessment by Monotherapy Products, H1 2015
Assessment by Combination Products, H1 2015
Number of Products by Stage and Target, H1 2015
Number of Products by Stage and Mechanism of Action, H1 2015
Number of Products by Stage and Route of Administration, H1 2015
Number of Products by Stage and Molecule Type, H1 2015
Acinetobacter Infections Therapeutics - Recent Pipeline Updates, H1 2015
Acinetobacter Infections - Dormant Projects, H1 2015

List of Figures
Number of Products under Development for Acinetobacter Infections, H1 2015
Number of Products under Development for Acinetobacter Infections - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Number of Products under Investigation by Universities/Institutes, H1 2015
Comparative Analysis by Early Stage Products, H1 2015
Assessment by Monotherapy Products, H1 2015
Number of Products by Top 10 Targets, H1 2015
Number of Products by Stage and Top 10 Targets, H1 2015
Number of Products by Top 10 Mechanism of Actions, H1 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015
Number of Products by Top 10 Routes of Administration, H1 2015
Number of Products by Stage and Top 10 Routes of Administration, H1 2015
Number of Products by Top 10 Molecule Types, H1 2015
Number of Products by Stage and Top 10 Molecule Types, H1 2015
Note: Product cover images may vary from those shown
3 of 4
Achaogen Inc.
Adenium Biotech ApS
AmpliPhi Biosciences Corporation
Aridis Pharmaceuticals LLC
AstraZeneca PLC
AvidBiotics Corp.
ConjuGon, Inc.
Emergent BioSolutions Inc.
FAB Pharma
LegoChem Biosciences, Inc
Melinta Therapeutics, Inc
Microbiotix, Inc.
Northern Antibiotics Oy
Nosopharm SAS
Novan, Inc.
Omnia Molecular Ltd.
Pfizer Inc.
Phylogica Limited
Sarepta Therapeutics, Inc.
Sealife PHARMA GMBH
Shionogi & Co., Ltd.
Synthetic Biologics, Inc.
Techulon, Inc.
Trana Discovery, Inc.
Vaxdyn, S.L.
Note: Product cover images may vary from those shown
4 of 4
Note: Product cover images may vary from those shown
Adroll
adroll